Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Pulmonary Arterial Hypertension

Drug Development Winrevair Seralutinib

Gossamer Bio Hit With Investor Class Action After PROSERA Miss, With June 1 Lead‑Plaintiff Deadline

Plaintiff firms are urging investors to seek lead‑plaintiff status by the June 1 deadline.

Gossamer Bio Faces Securities Class Action After PROSERA Failure, 80% Stock Plunge